ArticleCancer discovery2019
The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells.
Open access · greenAbstract read
In one paragraph
Article in Cancer discovery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 251 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
251citing papers in PubMed, 1 pooled it
14.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
251 citing papers in PubMed, 1 synthesis or guideline pooled it, 361 citations in OpenAlex.
- Acute myeloid leukemia with bipotential erythroid and megakaryocytic differentiation: a case series and literature review.Journal of hematopathology · 2025Pooled it
- Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia.Cancer research communications · 2025Trial
- Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study.The Lancet. Haematology · 2024Trial
- Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial.The Lancet. Haematology · 2024Trial
- Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates.Blood advances · 2023Trial
- Current and future therapies for acute myeloblastic leukemia.Journal of hematology & oncology · 2026Review
- Triptolide as a multi-target anticancer agent: molecular mechanisms and translational potential.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Wired to Survive: How AML Cytogenetics Shape Apoptotic Dependence and Venetoclax Resistance.Genes · 2026Review
- AI-enabled multi-omics pharmacogenomic modeling guides resistance-aware multitarget optimization of venetoclax therapy in acute myeloid leukemia.NPJ precision oncology · 2026Article
- Mechanisms and therapeutic opportunities of the ribotoxic stress response in cancer.Molecular oncology · 2026Review
- Glutathione metabolism-linked ferroptosis in human seminoma: a spatial multi-omics mapping study.Redox biology · 2026Article
- The Natural Quassinoid Brusatol Enhances Venetoclax Efficacy and Overcomes Resistance in Myeloid Leukemias.Cancer science · 2026Article
- m6A and NuRD complexes regulate monocytic differentiation and resistance to BCL2/BCL2L1 inhibitors in acute myeloid leukemia.Haematologica · 2026Article
- Comment on: "Clinical interrogation ofHaematologica · 2026Article
- A Nomogram Prediction Model and Scoring System for Resistance in Acute Myeloid Leukemia Patients Treated with Venetoclax Combined with Hypomethylating Agents.Current oncology (Toronto, Ont.) · 2026Article
- HDAC8 inhibition targets STAT3-MYC axis and synergizes with Venetoclax in KMT2A-rearranged acute myeloid leukemia.Leukemia · 2026Article
- Distinct stem cell identities converge into shared erythroid stress in ERCC6L2 disease and Shwachman-Diamond syndrome.HemaSphere · 2026Article
- AcTor, a novel mTOR stimulator, potentiates ixazomib for the treatment of acute myeloid leukemia.Molecular cancer · 2026Article
- MCL1 inhibition to enhance the efficacy of MYB targeting in pediatric acute myeloid leukemia.Cell death & disease · 2026Article
- Pervasive Cas9 expression driven by mammalian promoter activity in E. coli affects representation of CRISPR sgRNA libraries.Communications biology · 2026Article
191 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 1 country.
Tamilla NechiporukDivision of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon.
Stephen E KurtzDivision of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon.
Olga NikolovaKnight Cancer Institute, Oregon Health and Science University, Portland, Oregon.ORCID 0000-0001-8105-2440
Tingting LiuDivision of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon.
Courtney L JonesDivision of Hematology, University of Colorado Denver, Aurora, Colorado.
Angelo D'AlessandroDepartment of Biochemistry and Molecular Genetics, University of Colorado Denver, Aurora, Colorado.
Rachel Culp-HillDepartment of Biochemistry and Molecular Genetics, University of Colorado Denver, Aurora, Colorado.
Amanda d'AlmeidaDivision of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon.
Sunil K JoshiDivision of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon.
Mara RosenbergDivision of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon.ORCID 0000-0001-6400-3161
Cristina E TognonDivision of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon.
Alexey V DanilovDivision of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon.
Brian J DrukerDivision of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon.ORCID 0000-0001-8331-8206
Bill H ChangKnight Cancer Institute, Oregon Health and Science University, Portland, Oregon.ORCID 0000-0003-3783-1820
Shannon K McWeeneyKnight Cancer Institute, Oregon Health and Science University, Portland, Oregon.
Jeffrey W TynerDivision of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon. tynerj@ohsu.edu.ORCID 0000-0002-2133-0960
Oregon Health & Science University · USUniversity of Colorado Denver · USHoward Hughes Medical Institute · US
Funding
Understanding the origins of rapid recurrence of pancreatic cancer after resectionP30CA069533 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Luiz Eduardo Bertassoni · 1997 to 2026
$60.5MTumor Intrinsic and Microenvironmental Mechanisms Driving Drug Combination Efficacy and Resistance in AMLU54CA224019 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Anupriya Agarwal · 2017 to 2026
$13.9MFunctional Genomic Discovery of Pathway Targeted and Immune Modulatory Therapeutic Combinations in Hematologic MalignanciesU01CA217862 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI DRUKER, BRIAN J, TYNER, JEFFREY WALLACE · 2017 to 2021
$5.3MUV and p21 DegradationR01CA108947 · NCI · SIDNEY KIMMEL CANCER CENTER · PI FOTEDAR, RATI · 2005 to 2009
$1.7MDefining the stromal landscape that sustains AML drug resistanceF30CA239335 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI JOSHI, SUNIL KUMAR · 2019 to 2022
$187kHoward Hughes Medical InstituteNCI NIH HHS F30 CA239335NCI NIH HHS P30 CA069533NCI NIH HHS R01 CA108947NCI NIH HHS U01 CA217862NCI NIH HHS U54 CA224019
Abstract
To study mechanisms underlying resistance to the BCL2 inhibitor venetoclax in acute myeloid leukemia (AML), we used a genome-wide CRISPR/Cas9 screen to identify gene knockouts resulting in drug resistance. We validated
Indexed as
AnimalsAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsApoptosisBridged Bicyclo Compounds, HeterocyclicCell Line, TumorDrug Resistance, NeoplasmHumansLeukemia, Myeloid, AcuteMiceMice, Inbred NODMice, SCIDMitochondriaProto-Oncogene Proteins c-bcl-2SulfonamidesTumor Suppressor Protein p53Antineoplastic AgentsBCL2 protein, humanBridged Bicyclo Compounds, HeterocyclicProto-Oncogene Proteins c-bcl-2SulfonamidesTP53 protein, humanTumor Suppressor Protein p53venetoclax
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.